AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A method of treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level.

2 (original). A method as claimed in Claim 1 wherein the therapeutic level is such as to produce a TGF-β1/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing.

3 (original). A method as claimed in Claim 2 wherein the ratio is at least 0.75.

4 (original). A method as claimed in Claim 2 wherein the ratio is at least 1.

5 (original). A method as claimed in Claim 1 wherein the amount of oil administered is between 3 and 30 grams per day.

6 (original). A method as claimed in Claim 1 wherein the oil is administered orally.

7 (original). A method as claimed in Claim 1 wherein the dose is sufficient to administer at least 1 gram of γ-linolenic acid residues, as residues in the sn-2 position, excluding other γ-linolenic acid content of the oil.

8 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the amount of γ-linolenic acid in the sn-2 position in the dose of oil is sufficient to administer at least 2 grams of said sn-2 γ-linolenic acid.

9 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the dose is between 8 and 20 grams.

10 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein in addition to the γ-linolenic acid and linolenic acid fatty acid residues, the triglyceride includes an esterified fatty acid that is non-structural.

11 (original). A method as claimed in claim 10 wherein the triglyceride contains oleic acid residues.

12 (original). A method as claimed in claim 1 wherein the oil is that obtained from a fungus or a plant selected from the group consisting of Mucor and Borago species.

13 (original). A method as claimed in Claim 12 wherein the fungus or plant is selected from Mucor javanicus and Borago officianalis.

14 (original). A method as claimed in Claim 1 wherein the oil is a Borago oil in which the percentage of esterified γ-linolenic acid at the sn-2 position is at least 35% of fatty acid residues at that position.

15 (original). A method as claimed in Claim 14 wherein the percentage of esterified γ-linolenic acid at the sn-2 position is at least 39% of fatty acid residues at that position.

16 (original). A method as claimed in Claim 14 wherein the percentage of esterified γ-linolenic acid at the sn-2 position is at least 45% of fatty acid residues at that position.

17 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the fatty acid residues in the sn-1 and sn-3 position include linoleic, oleic and γ-linolenic acid residues.

18 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the triglyceride oil has an oleic acid content in one or both of the sn-1 and sn-3 positions of in excess of 12%.

19 (original). A method as claimed in Claim 1 wherein the oil is Mucor oil and, the total percentage of esterified γ-linolenic acid residues at the sn-2 position is at least 20% of fatty acid residues at that position.

20 (original). A method as claimed in Claim 19 wherein the triglyceride oil has in excess of 45% of the sn-2 fatty acid residues as oleic acid residues.

21 (original). A method as claimed in Claim 19 wherein the triglyceride oil has in excess of 50% of the sn-2 fatty acids as oleic acid residues.

22 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the triglyceride oil contains less than 5% monoenoic fatty acid residues as % total fatty acid residues.

23 (original). A method as claimed in Claim 22 wherein the triglyceride oil contains less than 5% in total erucic acid (22:1n-9), 24:1n-9 (nervonic acid) and 20:1n-9 (gadoleic acid) as a percentage of total fatty acid residues.

24 (currently amended). A method as claimed in Claim 22 ~~or 23~~ wherein the amount of said acid is between 1% and 5% of fatty acid residues in the oil.

25 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the oil has no added vitamin E.

26 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the amount of Vitamin E is between 0 and 0.1mg/g.

27 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein the neurodegenerative disease is arrested or neuronal function is restored.

28 (currently amended). A method as claimed in ~~any one of the preceding claims~~ claim 1 wherein treatment is for multiple sclerosis or the degenerative sequelae associated with head trauma, stroke and intracranial bleeds.

29 (original). A method as claimed in claim 28 wherein the treatment repairs lesions.

30 (currently amended). A method as claimed in Claim 1 ~~or 28~~ wherein the treatment uses a dose sufficient to relieve muscle spasticity and/or pain.

31 (currently amended). A method as claimed in Claim 1 ~~or 28~~ wherein the dosage is sufficient to improve cognitive function.

32 (currently amended). A method as claimed in Claim 1 ~~or 28~~ wherein the dosage is sufficient to eliminate relapses.

33 (currently amended). A method as claimed in Claim 1 ~~or 28~~ wherein the dosage is sufficient to improve the patients EDSS score by at least 1 unit over a period of 1 years treatment.

34 (currently amended). A method as claimed in Claim 1 or ~~Claim 28~~ wherein the dosage is sufficient to restore EDSS of a patient with EDSS above 2.5 to below 2 over a period of 1 years treatment.

35 (currently amended). Use of an oil as described in ~~any one of Claims 1 to 34~~ claim 1 for the manufacture of a medicament for the treatment of neurodegenerative disease.

36 (currently amended). A pharmaceutical composition for the treatment of neurodegenerative disease comprising a Borago or Mucor species triglyceride oil as described in ~~any one of Claims 14 to 26~~claim 14.